primaryid string | caseid string | caseversion string | i_f_code string | event_dt string | mfr_dt string | init_fda_dt string | fda_dt string | rept_cod string | auth_num string | mfr_num string | mfr_sndr string | lit_ref string | age string | age_cod string | age_grp string | sex string | e_sub string | wt string | wt_cod string | rept_dt string | to_mfr string | occp_cod string | reporter_country string | occr_country string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
228584031 | 22858403 | 1 | I | null | 20230818 | 20230824 | 20230824 | EXP | null | AT-NOVITIUMPHARMA-2023ATNVP01402 | NOVITIUM PHARMA | Franz Martin Fink.Case report: metoclopramide induced acute dystonic reaction in adolescent CYP2D6 poor metabolizers.Frontiers in Pharmacology.11-JUL-2023;14:1-5 | 14 | YR | T | M | Y | 62 | KG | 20230824 | null | HP | AT | AT |
228584041 | 22858404 | 1 | I | null | 20230816 | 20230824 | 20230824 | EXP | null | JP-STL-000133 | Stallion Laboratories | Saito S, Iijima M, Ikeguchi R, Ishizuka K, Kitagawa K. Four Cases of Suspected Levetiracetam-Induced Asymptomatic Rhabdomyolysis. Cureus. 2023 Jul 10;15(7):e41666. doi: 10.7759/cureus.41666. | 25 | YR | null | F | Y | null | null | 20230823 | null | HP | JP | JP |
228584061 | 22858406 | 1 | I | null | 20230820 | 20230824 | 20230824 | EXP | null | CA-002147023-NVSC2020CA079525 | SANDOZ | null | 44 | YR | null | F | Y | null | null | 20230824 | null | CN | CA | CA |
228584071 | 22858407 | 1 | I | null | 20230816 | 20230824 | 20230824 | EXP | null | JP-STL-000134 | Stallion Laboratories | Saito S, Iijima M, Ikeguchi R, Ishizuka K, Kitagawa K. Four Cases of Suspected Levetiracetam-Induced Asymptomatic Rhabdomyolysis. Cureus. 2023 Jul 10;15(7):e41666. doi: 10.7759/cureus.41666. | 32 | YR | null | M | Y | null | null | 20230823 | null | HP | JP | JP |
228584081 | 22858408 | 1 | I | null | 20230728 | 20230824 | 20230824 | EXP | null | US-SANDOZ-SDZ2023US017485 | SANDOZ | null | null | null | null | F | Y | 67.73 | KG | 20230824 | null | HP | US | US |
228584112 | 22858411 | 2 | F | 20230818 | 20230823 | 20230824 | 20230828 | EXP | null | US-ABBVIE-5378307 | ABBVIE | null | 67 | YR | null | F | Y | null | null | 20230828 | null | CN | US | US |
228584121 | 22858412 | 1 | I | null | 20230818 | 20230824 | 20230824 | EXP | null | HU-002147023-NVSC2023HU088347 | SANDOZ | null | null | null | E | F | Y | null | null | 20230824 | null | CN | HU | HU |
228584131 | 22858413 | 1 | I | null | 20230823 | 20230824 | 20230824 | EXP | null | NVSC2023US183901 | NOVARTIS | null | null | null | null | M | Y | null | null | 20230824 | null | HP | US | US |
228584141 | 22858414 | 1 | I | 20230821 | 20230821 | 20230824 | 20230824 | PER | null | US-AMGEN-USASP2023149180 | AMGEN | null | null | null | null | F | Y | null | null | 20230823 | null | CN | US | US |
228584151 | 22858415 | 1 | I | null | 20230821 | 20230824 | 20230824 | PER | null | US-BEIGENE-BGN-2023-008914 | BEIGENE | null | null | null | null | null | Y | null | null | 20230824 | null | CN | US | US |
228584161 | 22858416 | 1 | I | null | 20230823 | 20230824 | 20230824 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-118925 | BRISTOL MYERS SQUIBB | null | 73 | YR | E | F | Y | null | null | 20230824 | null | HP | US | US |
228584182 | 22858418 | 2 | F | 20230202 | 20230911 | 20230824 | 20230918 | EXP | PT-INFARMED-T202308-452 | PT-AMGEN-PRTSP2023148746 | AMGEN | null | 75 | YR | E | F | Y | null | null | 20230918 | null | MD | PT | PT |
228584191 | 22858419 | 1 | I | null | 20230821 | 20230824 | 20230824 | PER | null | US-AMGEN-USASP2023149526 | AMGEN | null | null | null | null | null | Y | null | null | 20230823 | null | PH | US | US |
228584201 | 22858420 | 1 | I | null | 20230821 | 20230824 | 20230824 | EXP | null | KR-ROCHE-3408710 | ROCHE | Park C, Lee H, Kang K, Lee W, Do Y, Kwak J, Shin H, Kim S, Yi J, Lim S, Lee J, Yang D, Byun J, Yoon S and Koh Y Combination of acalabrutinib with rituximab and lenalidomide in relapsed/refractory B cell non-Hodgkin lymphoma [Abstract no: 326]. DOI:10.1002/hon.3164_326. Hematological Oncology 2023 Jun 01;41 (S2):443-. | null | null | null | null | Y | null | null | 20230824 | null | HP | KR | null |
228584211 | 22858421 | 1 | I | null | 20230816 | 20230824 | 20230824 | EXP | null | US-BEIGENE-BGN-2023-008725 | BEIGENE | null | null | null | null | null | Y | null | null | 20230824 | null | CN | US | US |
228584221 | 22858422 | 1 | I | 20230627 | 20230821 | 20230824 | 20230824 | EXP | null | CN-ROCHE-3409292 | ROCHE | null | 63 | YR | null | M | Y | 74 | KG | 20230824 | null | HP | CN | null |
228584231 | 22858423 | 1 | I | null | 20230821 | 20230824 | 20230824 | EXP | null | PL-NOVITIUMPHARMA-2023PLNVP01407 | NOVITIUM PHARMA | Konrad Szymanski.Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review.Frontiers in Immunology.12-JUL-2023;14:1-9 | null | null | E | F | Y | null | null | 20230824 | null | HP | PL | PL |
228584242 | 22858424 | 2 | F | null | 20230606 | 20230824 | 20230828 | EXP | null | US-SANDOZ INC.-SDZ2023US017432 | SANDOZ | null | null | null | null | F | Y | null | null | 20230828 | null | HP | US | US |
228584251 | 22858425 | 1 | I | null | 20230811 | 20230824 | 20230824 | EXP | null | US-PADAGIS-2023PAD01169 | PADAGIS | Ahmad TK, Huynha LM, Raghub R, Solimanc KM, Henrya W, Sallama A. Intravitreal Triamcinolone Acetonide Presents a Diagnostic Challenge on Noncontrast Computed Tomography. Case Reports in Opthomology. 2022;13(1):243-246 | null | null | null | null | Y | null | null | 20230824 | null | HP | US | US |
228584261 | 22858426 | 1 | I | 20221216 | 20230815 | 20230824 | 20230824 | EXP | FR-AFSSAPS-CN2023000695 | FR-SANDOZ-SDZ2023FR017673 | SANDOZ | null | 37 | YR | null | M | Y | null | null | 20230824 | null | MD | FR | FR |
228584271 | 22858427 | 1 | I | null | 20230605 | 20230824 | 20230824 | EXP | null | US-SANDOZ-SDZ2023US017519 | SANDOZ | null | null | null | null | F | Y | 113.64 | KG | 20230824 | null | HP | US | US |
228584281 | 22858428 | 1 | I | null | 20230815 | 20230824 | 20230824 | EXP | null | US-JNJFOC-20230834529 | JOHNSON AND JOHNSON | null | null | null | null | null | Y | null | null | 20230824 | null | MD | US | US |
228584291 | 22858429 | 1 | I | 20171130 | 20230816 | 20230824 | 20230824 | EXP | null | CA-002147023-PHHY2017CA179388 | SANDOZ | null | 63 | YR | null | F | Y | null | null | 20230824 | null | CN | CA | CA |
228584312 | 22858431 | 2 | F | null | 20230921 | 20230824 | 20230926 | PER | null | US-LUNDBECK-DKLU3066426 | LUNDBECK | null | 55 | YR | null | M | Y | null | null | 20230927 | null | CN | US | US |
228584321 | 22858432 | 1 | I | null | 20230814 | 20230824 | 20230824 | EXP | null | DE-SANDOZ-SDZ2023DE015194 | SANDOZ | null | null | null | null | F | Y | null | null | 20230824 | null | CN | DE | DE |
228584331 | 22858433 | 1 | I | 20230616 | 20230731 | 20230824 | 20230824 | EXP | null | CA-SANDOZ-SDZ2023CA008427 | SANDOZ | null | 78 | YR | null | M | Y | null | null | 20230824 | null | PH | CA | CA |
228584341 | 22858434 | 1 | I | null | 20230608 | 20230824 | 20230824 | EXP | null | US-SANDOZ-SDZ2023US017422 | SANDOZ | null | null | null | null | F | Y | 109.09 | KG | 20230824 | null | MD | US | US |
228584351 | 22858435 | 1 | I | 20230723 | 20230811 | 20230824 | 20230824 | EXP | null | FR-VALIDUS PHARMACEUTICALS LLC-FR-VDP-2023-016229 | VALIDUS | null | null | null | null | null | Y | null | null | 20230824 | null | MD | FR | FR |
228584361 | 22858436 | 1 | I | 20230725 | 20230725 | 20230824 | 20230824 | EXP | null | US-SANDOZ-SDZ2023US016683 | SANDOZ | null | 52 | YR | null | F | Y | 91.61 | KG | 20230824 | null | MD | US | US |
228584371 | 22858437 | 1 | I | null | 20230815 | 20230824 | 20230824 | EXP | null | CZ-SANDOZ-SDZ2023CZ000205 | SANDOZ | null | 6 | YR | null | M | Y | 16.5 | KG | 20230824 | null | MD | CZ | CZ |
228584381 | 22858438 | 1 | I | null | 20230821 | 20230824 | 20230824 | PER | null | US-ELI_LILLY_AND_COMPANY-US202308013433 | ELI LILLY AND CO | null | null | null | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584411 | 22858441 | 1 | I | 20230801 | 20230822 | 20230824 | 20230824 | PER | null | US-ELI_LILLY_AND_COMPANY-US202308013687 | ELI LILLY AND CO | null | 59 | YR | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584421 | 22858442 | 1 | I | 20230821 | 20230822 | 20230824 | 20230824 | PER | null | US-ELI_LILLY_AND_COMPANY-US202308013892 | ELI LILLY AND CO | null | 66 | YR | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584431 | 22858443 | 1 | I | 20230821 | 20230822 | 20230824 | 20230824 | PER | null | US-ELI_LILLY_AND_COMPANY-US202308013683 | ELI LILLY AND CO | null | 55 | YR | null | null | Y | null | null | 20230824 | null | CN | US | US |
228584441 | 22858444 | 1 | I | 20230820 | 20230821 | 20230824 | 20230824 | PER | null | US-ELI_LILLY_AND_COMPANY-US202308012949 | ELI LILLY AND CO | null | 52 | YR | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584451 | 22858445 | 1 | I | null | 20230818 | 20230824 | 20230824 | PER | null | US-ELI_LILLY_AND_COMPANY-US202308012055 | ELI LILLY AND CO | null | null | null | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584461 | 22858446 | 1 | I | null | 20230822 | 20230824 | 20230824 | PER | null | US-ELI_LILLY_AND_COMPANY-US202308013858 | ELI LILLY AND CO | null | null | null | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584471 | 22858447 | 1 | I | null | 20230814 | 20230824 | 20230824 | PER | null | US-ELI_LILLY_AND_COMPANY-US202308008733 | ELI LILLY AND CO | null | 59 | YR | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584481 | 22858448 | 1 | I | 20230821 | 20230821 | 20230824 | 20230824 | PER | null | US-ELI_LILLY_AND_COMPANY-US202308013017 | ELI LILLY AND CO | null | 65 | YR | null | null | Y | null | null | 20230824 | null | CN | US | US |
228584491 | 22858449 | 1 | I | null | 20230816 | 20230824 | 20230824 | PER | null | US-ELI_LILLY_AND_COMPANY-US202308011535 | ELI LILLY AND CO | null | 48 | YR | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584501 | 22858450 | 1 | I | 20230821 | 20230822 | 20230824 | 20230824 | PER | null | US-ELI_LILLY_AND_COMPANY-US202308013685 | ELI LILLY AND CO | null | 53 | YR | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584521 | 22858452 | 1 | I | 20230822 | 20230822 | 20230824 | 20230824 | PER | null | US-AMGEN-USASP2023148854 | AMGEN | null | null | null | null | M | Y | null | null | 20230824 | null | MD | US | US |
228584531 | 22858453 | 1 | I | 20230821 | 20230822 | 20230824 | 20230824 | PER | null | US-AMGEN-USASP2023148874 | AMGEN | null | 67 | YR | E | F | Y | null | null | 20230824 | null | CN | US | US |
228584541 | 22858454 | 1 | I | 20230801 | 20230821 | 20230824 | 20230824 | PER | null | US-AMGEN-USASP2023149461 | AMGEN | null | 74 | YR | E | F | Y | null | null | 20230824 | null | CN | US | US |
228584571 | 22858457 | 1 | I | null | 20200107 | 20230824 | 20230824 | PER | null | US-009507513-2306USA004221 | MERCK | null | null | null | null | null | Y | null | null | 20230824 | null | MD | US | US |
228584581 | 22858458 | 1 | I | null | 20230821 | 20230824 | 20230824 | PER | null | US-AMGEN-USASP2023149519 | AMGEN | null | null | null | null | null | Y | null | null | 20230824 | null | CN | US | US |
228584593 | 22858459 | 3 | F | 20230816 | 20230823 | 20230824 | 20230830 | PER | null | US-AMGEN-USASP2023148330 | AMGEN | null | 82 | YR | E | F | Y | null | null | 20230830 | null | HP | US | US |
228584604 | 22858460 | 4 | F | 20230801 | 20230914 | 20230824 | 20230916 | PER | null | US-AMGEN-USASP2023149106 | AMGEN | null | 50 | YR | A | F | Y | 139 | KG | 20230915 | null | HP | US | US |
228584632 | 22858463 | 2 | F | 20230608 | 20230825 | 20230824 | 20230831 | EXP | null | AU-SA-2023SA201552 | SANOFI AVENTIS | null | 81 | YR | E | F | Y | null | null | 20230831 | null | HP | AU | AU |
228584642 | 22858464 | 2 | F | 20230731 | 20230905 | 20230824 | 20230911 | EXP | null | AT-SAKK-2023SA238075AA | SANOFI AVENTIS | null | 80 | YR | E | M | Y | 73 | KG | 20230911 | null | HP | AT | AT |
228584661 | 22858466 | 1 | I | 20230101 | 20230821 | 20230824 | 20230824 | EXP | null | CA-JNJFOC-20230848557 | JOHNSON AND JOHNSON | null | 73 | YR | E | F | Y | null | null | 20230824 | null | CN | CA | CA |
228584671 | 22858467 | 1 | I | 20230206 | 20230822 | 20230824 | 20230824 | EXP | null | DE-SANDOZ-SDZ2023DE017303 | SANDOZ | null | 58 | YR | null | M | Y | null | null | 20230824 | null | MD | DE | DE |
228584681 | 22858468 | 1 | I | null | 20230818 | 20230824 | 20230824 | PER | null | US-Blueprint Medicines Corporation-SP-US-2023-001262 | BLUEPRINT MEDICINES | null | null | null | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584692 | 22858469 | 2 | F | 20230814 | 20230926 | 20230824 | 20230928 | EXP | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-118879 | BRISTOL MYERS SQUIBB | null | 80 | YR | E | M | Y | null | null | 20230928 | null | CN | US | US |
228584701 | 22858470 | 1 | I | null | 20230821 | 20230824 | 20230824 | EXP | null | CN-SANDOZ-SDZ2023CN016951 | SANDOZ | Liu Xiaolong , Pang Jing. One critically ill case of severe rhabdomyolysis syndrome was reported. Chinese Folk Therapy. 2023;31:102-104 | 67 | YR | null | F | Y | null | null | 20230824 | null | HP | CN | CN |
228584711 | 22858471 | 1 | I | null | 20230728 | 20230824 | 20230824 | EXP | null | US-SANDOZ-SDZ2023US017474 | SANDOZ | null | null | null | null | M | Y | null | null | 20230824 | null | CN | US | US |
228584721 | 22858472 | 1 | I | 20230320 | 20230822 | 20230824 | 20230824 | EXP | null | AE-ROCHE-3357640 | ROCHE | null | 44 | YR | null | F | Y | null | null | 20230824 | null | CN | AE | null |
228584731 | 22858473 | 1 | I | null | 20230814 | 20230824 | 20230824 | EXP | null | ZA-LUPIN PHARMACEUTICALS INC.-2023-07033 | LUPIN | null | null | null | null | null | Y | null | null | 20230824 | null | CN | ZA | ZA |
228584741 | 22858474 | 1 | I | null | 20230818 | 20230824 | 20230824 | 30DAY | null | US-GSK-US2023112747 | GLAXOSMITHKLINE | null | null | null | A | M | Y | null | null | 20230824 | null | CN | US | US |
228584751 | 22858475 | 1 | I | null | 20230814 | 20230824 | 20230824 | EXP | null | US-GSK-US2023110200 | GLAXOSMITHKLINE | null | null | null | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584761 | 22858476 | 1 | I | null | 20230821 | 20230824 | 20230824 | EXP | null | US-GLAXOSMITHKLINE-USCH2023040612 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 20230824 | null | CN | US | US |
228584771 | 22858477 | 1 | I | null | 20230817 | 20230824 | 20230824 | EXP | null | US-JNJFOC-20230844411 | JOHNSON AND JOHNSON | null | null | null | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584791 | 22858479 | 1 | I | null | 20230821 | 20230824 | 20230824 | PER | null | US-TAKEDA-2023TUS081999 | TAKEDA | null | null | null | null | M | Y | 64 | KG | 20230824 | null | MD | US | US |
228584801 | 22858480 | 1 | I | null | 20230815 | 20230824 | 20230824 | EXP | null | CA-APOTEX-2023AP012365 | APOTEX | null | 27 | YR | null | F | Y | null | null | 20230824 | null | HP | CA | CA |
228584821 | 22858482 | 1 | I | null | 20230822 | 20230824 | 20230824 | PER | null | US-AMGEN-USASP2023149866 | AMGEN | null | null | null | null | null | Y | null | null | 20230824 | null | PH | US | US |
228584831 | 22858483 | 1 | I | null | 20230818 | 20230824 | 20230824 | EXP | null | CA-TAKEDA-2023TUS081496 | TAKEDA | null | null | null | null | M | Y | null | null | 20230824 | null | CN | CA | CA |
228584841 | 22858484 | 1 | I | 20190730 | 20230820 | 20230824 | 20230824 | EXP | null | US-ROCHE-2903648 | ROCHE | null | 73 | YR | null | F | Y | 63.5 | KG | 20230824 | null | MD | US | null |
228584861 | 22858486 | 1 | I | null | 20230817 | 20230824 | 20230824 | 30DAY | null | US-SANDOZ INC.-SDZ2023US017197 | SANDOZ | null | 31 | YR | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584872 | 22858487 | 2 | F | 20230811 | 20230914 | 20230824 | 20230921 | EXP | null | CZ-SANDOZ INC.-SDZ2023CZ016985 | SANDOZ | null | 35 | YR | null | F | Y | 51.5 | KG | 20230921 | null | MD | CZ | CZ |
228584881 | 22858488 | 1 | I | null | 20230820 | 20230824 | 20230824 | EXP | null | NVSC2023CA182833 | NOVARTIS | null | 38 | YR | null | F | Y | null | null | 20230824 | null | HP | CA | CA |
228584891 | 22858489 | 1 | I | null | 20230818 | 20230824 | 20230824 | PER | null | US-AMGEN-USASP2023148720 | AMGEN | null | 54 | YR | A | F | Y | null | null | 20230824 | null | MD | US | US |
228584901 | 22858490 | 1 | I | null | 20230821 | 20230824 | 20230824 | EXP | null | US-JNJFOC-20230848367 | JOHNSON AND JOHNSON | null | null | null | null | null | Y | null | null | 20230824 | null | CN | US | US |
228584911 | 22858491 | 1 | I | 20230103 | 20230821 | 20230824 | 20230824 | EXP | AT-EMA-DD-20230816-7180175-110432 | AT-JNJFOC-20230849316 | JOHNSON AND JOHNSON | null | 61 | YR | A | M | Y | 67 | KG | 20230824 | null | MD | AT | AT |
228584921 | 22858492 | 1 | I | null | 20230823 | 20230824 | 20230824 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-118931 | BRISTOL MYERS SQUIBB | null | 75 | YR | E | M | Y | null | null | 20230824 | null | HP | US | US |
228584941 | 22858494 | 1 | I | null | 20230823 | 20230824 | 20230824 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-118933 | BRISTOL MYERS SQUIBB | null | 46 | YR | A | M | Y | null | null | 20230824 | null | HP | US | US |
228584951 | 22858495 | 1 | I | 20230725 | 20230817 | 20230824 | 20230824 | EXP | null | CN-ROCHE-3407633 | ROCHE | null | 65 | YR | null | F | Y | 49 | KG | 20230824 | null | HP | CN | null |
228584963 | 22858496 | 3 | F | 20220101 | 20230913 | 20230824 | 20230918 | PER | null | US-GILEAD-2023-0641112 | GILEAD | null | 57 | YR | A | M | Y | null | null | 20230918 | null | LW | US | US |
228584971 | 22858497 | 1 | I | null | 20230801 | 20230824 | 20230824 | EXP | null | US-SANDOZ INC.-SDZ2023US017918 | SANDOZ | null | null | null | null | M | Y | null | null | 20230824 | null | MD | US | US |
228584981 | 22858498 | 1 | I | 20230601 | 20230816 | 20230824 | 20230824 | EXP | null | US-GSK-US2023111990 | GLAXOSMITHKLINE | null | 68 | YR | null | F | Y | null | null | 20230824 | null | CN | US | US |
228584991 | 22858499 | 1 | I | null | 20230818 | 20230824 | 20230824 | 30DAY | null | US-GSK-US2023112758 | GLAXOSMITHKLINE | null | null | null | null | F | Y | null | null | 20230824 | null | CN | US | US |
228585002 | 22858500 | 2 | F | null | 20230824 | 20230824 | 20230912 | 30DAY | null | CO-JNJFOC-20230854798 | JOHNSON AND JOHNSON | null | null | null | null | null | Y | null | null | 20230910 | null | CN | CO | CO |
228585011 | 22858501 | 1 | I | 20230809 | 20230822 | 20230824 | 20230824 | EXP | null | US-ABBVIE-5378574 | ABBVIE | null | 66 | YR | null | F | Y | null | null | 20230824 | null | CN | US | US |
228585021 | 22858502 | 1 | I | 20110101 | 20230508 | 20230824 | 20230824 | EXP | null | US-ENDO PHARMACEUTICALS INC-2023-001958 | ENDO | null | null | null | null | F | Y | null | null | 20230824 | null | CN | US | US |
228585032 | 22858503 | 2 | F | null | 20230817 | 20230824 | 20230824 | EXP | null | CO-002147023-NVSC2021CO192372 | SANDOZ | null | null | null | null | F | Y | null | null | 20230824 | null | CN | CO | CO |
228585051 | 22858505 | 1 | I | 20230601 | 20230817 | 20230824 | 20230824 | PER | null | US-ABBVIE-5374423 | ABBVIE | null | null | null | null | null | Y | null | null | 20230824 | null | MD | US | US |
228585063 | 22858506 | 3 | F | 20230101 | 20230908 | 20230824 | 20230925 | PER | null | US-AMGEN-USASP2023146606 | AMGEN | null | 69 | YR | E | F | Y | null | null | 20230924 | null | CN | US | US |
228585071 | 22858507 | 1 | I | null | 20230621 | 20230824 | 20230824 | EXP | null | US-SANDOZ INC.-SDZ2023US017808 | SANDOZ | null | null | null | null | F | Y | null | null | 20230824 | null | HP | US | US |
228585081 | 22858508 | 1 | I | null | 20230816 | 20230824 | 20230824 | EXP | null | CA-APOTEX-2023AP012434 | APOTEX | null | 29 | YR | null | F | Y | null | null | 20230824 | null | HP | CA | CA |
228585091 | 22858509 | 1 | I | null | 20230821 | 20230824 | 20230824 | EXP | null | US-AstraZeneca-2023A192016 | ASTRAZENECA | null | null | null | null | M | Y | null | null | 20230824 | null | CN | US | null |
228585101 | 22858510 | 1 | I | null | 20230816 | 20230824 | 20230824 | EXP | null | PA-002147023-NVSC2023PA099817 | SANDOZ | null | null | null | null | F | Y | null | null | 20230824 | null | CN | PA | PA |
228585111 | 22858511 | 1 | I | null | 20230817 | 20230824 | 20230824 | EXP | null | US-AstraZeneca-2023A188493 | ASTRAZENECA | null | null | null | null | F | Y | null | null | 20230824 | null | CN | US | null |
228585121 | 22858512 | 1 | I | null | 20230508 | 20230824 | 20230824 | EXP | null | US-ENDO PHARMACEUTICALS INC-2023-001959 | ENDO | null | null | null | null | F | Y | null | null | 20230824 | null | CN | US | US |
228585132 | 22858513 | 2 | F | null | 20230814 | 20230824 | 20230825 | PER | null | NVSC2023US179126 | NOVARTIS | null | 61 | YR | null | F | Y | null | null | 20230825 | null | CN | US | US |
228585141 | 22858514 | 1 | I | null | 20230731 | 20230824 | 20230824 | EXP | null | US-SANDOZ INC.-SDZ2023US017940 | SANDOZ | null | null | null | null | F | Y | null | null | 20230824 | null | MD | US | US |
228585151 | 22858515 | 1 | I | 20230701 | 20230817 | 20230824 | 20230824 | EXP | null | US-JNJFOC-20230842535 | JOHNSON AND JOHNSON | null | 83 | YR | E | F | Y | null | null | 20230824 | null | HP | US | US |
228585161 | 22858516 | 1 | I | null | 20230728 | 20230824 | 20230824 | EXP | null | US-SANDOZ INC.-SDZ2023US017775 | SANDOZ | null | null | null | null | F | Y | 76.82 | KG | 20230824 | null | HP | US | US |
228585171 | 22858517 | 1 | I | null | 20230821 | 20230824 | 20230824 | PER | null | US-AMGEN-USASP2023149133 | AMGEN | null | null | null | null | null | Y | null | null | 20230824 | null | CN | US | US |
228585183 | 22858518 | 3 | F | 20230801 | 20230911 | 20230824 | 20230918 | PER | null | US-AMGEN-USASP2023148930 | AMGEN | null | 52 | YR | A | F | Y | null | null | 20230917 | null | HP | US | US |
228585191 | 22858519 | 1 | I | 20230101 | 20230818 | 20230824 | 20230824 | PER | null | US-UNITED THERAPEUTICS-UNT-2023-023046 | UNITED THERAPEUTICS | null | null | null | null | M | Y | 68.481 | KG | 20230824 | null | CN | US | US |
228585201 | 22858520 | 1 | I | null | 20230822 | 20230824 | 20230824 | PER | null | US-AMGEN-USASP2023149393 | AMGEN | null | null | null | null | null | Y | null | null | 20230824 | null | CN | US | US |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.